Bluejay Therapeutics

Developing innovative cures for infectious diseases with the first target indication of chronic HBV infection

Add To Watchlist
General Information
Company Name
Bluejay Therapeutics
Founded Year
2020
Location (Offices)
United States +1
Founders / Decision Makers
Christopher Holterhoff - Senior Vice President, Head of Business Development Hassan Javanbakht - Chief Scientific Officer Kevin Lin - VP, Development Nancy Shulman - Chief Medical Officer Keting Chu - Founder, Chief Executive Officer & Chairman of the Board Jeff Zablocki - VP, Head of Chemistry
Number of Employees
31
Industries
Biotechnology, Health Care, Pharmaceutical
Funding Stage
Series C
Social Media

Bluejay Therapeutics - Company Profile

Bluejay Therapeutics is a biotechnology startup founded in 2019 in the United States, with a focus on developing innovative cures for infectious diseases, specifically targeting chronic HBV infection. The company has exclusively licensed global rights to advance several HBV programs, including a best-in-class anti-HBsAg monoclonal antibody. Their recent milestone includes a significant $182.00M Series C investment on 09 May 2024, with support from a diverse group of investors such as Novo Holdings, RA Capital Management, RiverVest, T. Rowe Price, Wellington Management, Octagon Capital Advisors, Unicorn Capital Partners, Arkin Bio Ventures, Frazier Life Sciences, HBM Healthcare Investments AG. With a clear mission and strong financial backing, Bluejay Therapeutics is poised to make a significant impact in the biotechnology, healthcare, and pharmaceutical industries.

Taxonomy: infectious diseases, HBV infection, anti-HBsAg monoclonal antibody, drug development, biopharmaceuticals, global licensing, chronic infections, cure development, innovative therapies

Funding Rounds & Investors of Bluejay Therapeutics (3)

View All
Funding Stage Amount No. Investors Investors Date
Series C $182.00M 10
Novo Holdings, investor in Bluejay Therapeutics's Series C round HBM Healthcare Investments, investor in Bluejay Therapeutics's Series C round RA Capital Management, investor in Bluejay Therapeutics's Series C round RiverVest, investor in Bluejay Therapeutics's Series C round T. Rowe Price, investor in Bluejay Therapeutics's Series C round Wellington Management, investor in Bluejay Therapeutics's Series C round Octagon Capital Advisors, investor in Bluejay Therapeutics's Series C round Unicorn Capital Partners, investor in Bluejay Therapeutics's Series C round Frazier Life Sciences, investor in Bluejay Therapeutics's Series C round
Arkin Bio Ventures 		09 May 2024
Series B $41.00M - 16 Aug 2022
Venture Round $19.24M - 17 Jun 2021

Latest News of Bluejay Therapeutics

View All

No recent news or press coverage available for Bluejay Therapeutics.

Similar Companies to Bluejay Therapeutics

View All
Chromis Therapeutics - Similar company to Bluejay Therapeutics
Chromis Therapeutics
Replicor Inc. - Similar company to Bluejay Therapeutics
Replicor Inc. 292 million people have chronic hepatitis B. We're developing the cure.
Bluejay Advisors - Similar company to Bluejay Therapeutics
Bluejay Advisors Advising in Transportation and Logistics
Bluejay Labs - Similar company to Bluejay Therapeutics
Bluejay Labs Simple and th😍ughtful web products
Arbutus Biopharma Corporation - Similar company to Bluejay Therapeutics
Arbutus Biopharma Corporation
Circle Decoration Circle Decoration

Want to dive deeper into Bluejay Therapeutics? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now